Gland Pharma Limited — Investor Meet, 10-02-2025: Analysts/Institutional Investor Meet/Con. Call Updates

1. **Financial Performance**: Gland Pharma reported consolidated revenue of ₹13,841 million for Q3 FY25, with a consolidated EBITDA of ₹3,600 million, representing a margin of 26%, which is a 100 basis points increase year-on-year. The base business (excluding Cenexi) saw an 8% YoY decline in revenue to ₹10,123 million, primarily due to volume degrowth in key products, although new product launches helped mitigate some losses. The EBITDA margin for the base business improved to 39% from 34% in the same quarter last year, attributed to a favorable product mix and effective cost management.

2. **Future Outlook and Growth Drivers**: Management is focused on regaining lost volumes in upcoming quarters and remains optimistic about future growth, leveraging 13 new molecule launches in the U.S. market during Q3. The company anticipates a recovery from temporary disruptions and expects the robust performance in complex product filings, which represent a significant market opportunity.

3. **Order Book and Operational Updates**: Cenexi generated revenue of €41 million in Q3, below expectations due to reduced manufacturing activity from regulatory audits. However, Cenexi improved its gross margin to 77% from 75% YoY. The overall order book for Cenexi is reported at approximately €60 million.

4. **Analyst Q&A Insights (Detailed)**:

- **Revenue and Profitability**: Analysts questioned revenue declines in the U.S., primarily attributable to delayed shipments of key products, with an anticipated Q-o-Q recovery. Management clarified that while revenue dipped, margins improved thanks to product mix and cost control.

- **Market Position and Competitive Landscape**: Analysts noted competitive pressures from Chinese producers, especially in heparin and Enoxa markets, suggesting a potential weakening of competition due to tariff dynamics.

- **Operational Challenges or Risks**: Supply chain lapses and regulatory challenges impacted performance metrics. Management remains confident post-regulatory submissions.

- **Capex and Capital Allocation**: There are extensive capex plans totaling around $80 million to $100 million for biosimilars, alongside ongoing assessments for additional GLP-1 manufacturing capacities.

- **Strategic Priorities and Long-Term Vision**: Focus on expanding in key international markets and strategic partnerships to revolutionize product offerings and strengthen market position.

5. **Market or Regulatory Updates**: The company has received positive regulatory feedback from FDA inspections and is gearing up to enhance operational capabilities to meet growing demands.

6. **Strategic Focus Areas**: Key themes include enhancing R&D efficiencies, focusing on innovative therapies, and revitalizing operational capacities while maintaining quality and cost leadership across markets.

7. **Investor Insight**: Given Gland Pharma's solid EBITDA margin improvements, strategic launches, and potential for market recovery, it’s advisable to consider a favorable stance towards holding or purchasing shares, reflecting on the company's long-term growth initiatives and operational resilience.